arrow
D

Daniel O'Neill

biopharmaceutical r&d
H指数:15
被引数:883

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions

AZ14289671 是一种高选择性的血脑屏障穿透性不可逆TKI,可靶向EGFRExon20插入突变。

2025-08-250
OAAI
Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer
2024-04-249
OAAI
Discovery and Optimization of the First ATP Competitive Type-III c-MET Inhibitor
2023-06-218
OAAI
Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance
2021-09-0721
PRE
Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR)
2019-07-011
PRE
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
2018-04-3084
OAAI
Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer
2012-04-013
PRE